Janssen Biotech and Protagonist Therapeutics inked a potentially $990 million global codevelopment and commercialization deal for Protagonist&39;s oral peptide IL23 receptor antagonist PTG200 for treating inflammatory bowel disease IBD and for all othe...
↧